In a setback to Mylan Pharmaceuticals, the Ohio House of Representatives on Wednesday unanimously approved a bill that would allow pharmacists to substitute alternatives for the pricey EpiPen allergic-reaction device without requiring a new prescription from a physician.

The bill must still pass a Senate vote, but it has the potential for altering the competitive landscape, since pharmacists in these states are currently prohibited from unilaterally making any substitutions for the device. Similar legislation has been introduced in four other states — New York, New Jersey, Hawaii, and Vermont — but have not progressed this far.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy